Texas Yale Capital Corp. Sells 10,180 Shares of Novo Nordisk A/S (NYSE:NVO)

Key Points

• Texas Yale Capital Corp. reduced its holdings in Novo Nordisk A/S by 30.6%, selling 10,180 shares and now owning 23,041 shares worth approximately $1.6 million.
• Institutional investors hold 11.54% of Novo Nordisk’s stock, with notable increases from Nuveen Asset Management and Clearbridge Investments in the last quarter.
• The company's stock price opened at $71.67, with a market capitalization of $320 billion, and has a consensus rating of "Hold" with a price target of $112.00.

Texas Yale Capital Corp. lessened its holdings in Novo Nordisk A/S (NYSE:NVO - Free Report) by 30.6% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 23,041 shares of the company's stock after selling 10,180 shares during the quarter. Texas Yale Capital Corp.'s holdings in Novo Nordisk A/S were worth $1,600,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of NVO. Nuveen Asset Management LLC boosted its stake in shares of Novo Nordisk A/S by 73.2% in the 4th quarter. Nuveen Asset Management LLC now owns 6,244,931 shares of the company's stock valued at $537,189,000 after purchasing an additional 2,639,693 shares during the last quarter. Two Sigma Investments LP bought a new position in shares of Novo Nordisk A/S in the 4th quarter valued at about $158,657,000. Clearbridge Investments LLC boosted its stake in shares of Novo Nordisk A/S by 59.8% in the 4th quarter. Clearbridge Investments LLC now owns 4,283,317 shares of the company's stock valued at $368,451,000 after purchasing an additional 1,602,549 shares during the last quarter. Bank of America Corp DE raised its position in shares of Novo Nordisk A/S by 8.1% in the 4th quarter. Bank of America Corp DE now owns 15,492,384 shares of the company's stock valued at $1,332,655,000 after acquiring an additional 1,165,955 shares during the period. Finally, Northern Trust Corp raised its position in shares of Novo Nordisk A/S by 26.8% in the 4th quarter. Northern Trust Corp now owns 4,689,098 shares of the company's stock valued at $403,356,000 after acquiring an additional 991,022 shares during the period. Institutional investors own 11.54% of the company's stock.

Novo Nordisk A/S Stock Performance

Shares of NVO stock opened at $71.67 on Monday. The company has a debt-to-equity ratio of 0.70, a quick ratio of 0.56 and a current ratio of 0.74. The company has a market capitalization of $320.00 billion, a P/E ratio of 21.20, a price-to-earnings-growth ratio of 1.38 and a beta of 0.64. The company's 50 day moving average price is $70.67 and its two-hundred day moving average price is $73.63. Novo Nordisk A/S has a 52 week low of $57.00 and a 52 week high of $139.74.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported $0.92 EPS for the quarter, hitting the consensus estimate of $0.92. The firm had revenue of $11.87 billion for the quarter. Novo Nordisk A/S had a net margin of 34.52% and a return on equity of 80.94%. On average, analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Analyst Ratings Changes

NVO has been the topic of a number of analyst reports. Wall Street Zen upgraded shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research report on Saturday, June 14th. BMO Capital Markets reiterated a "market perform" rating and issued a $64.00 price target (down from $105.00) on shares of Novo Nordisk A/S in a research report on Thursday, April 17th. Guggenheim downgraded shares of Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research report on Thursday, April 17th. BNP Paribas initiated coverage on shares of Novo Nordisk A/S in a research report on Tuesday, April 15th. They issued an "underperform" rating on the stock. Finally, Dbs Bank downgraded shares of Novo Nordisk A/S to a "sell" rating in a research report on Friday, April 25th. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $112.00.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.